The Roles of Macrophages and Nitric Oxide in Interleukin-3-Enhanced HSV-Sr39tk-Mediated Prodrug Therapy

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Yu, Ching Fang ^a   Hong, Ji Hong ^b,c   Chiang, Chi Shiun ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GANCICLOVIR; INTERLEUKIN 3; INTERLEUKIN 4; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; SITIMAGENE CERADENOVEC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; INTERLEUKIN 3 GENE; MACROPHAGE FUNCTION; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SPLEEN LYMPHOCYTE; TH1 CELL; UPREGULATION;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; GANCICLOVIR; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTERLEUKIN-3; MACROPHAGES; MALE; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PRODRUGS; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; TH1 CELLS; THYMIDINE KINASE; TRANSFECTION;

EID: 84874142747     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056508     Document Type: Article

References (35)

1. Moolten FL, (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281.
2. Fillat C, Carrio M, Cascante A, Sangro B, (2003) Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 3: 13-26.
3. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, et al. (1977) Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A 74: 5716-5720.
4. Freeman SM, Ramesh R, Shastri M, Munshi A, Jensen AK, et al. (1995) The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. Cancer Lett 92: 167-174.
5. Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM, (1996) In vivo analysis of the 'bystander effect': a cytokine cascade. Exp Hematol 24: 829-838.
6. van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA, (2002) Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther 2: 307-322.
7. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, et al. (1996) Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 3: 85-92.
8. Black ME, Kokoris MS, Sabo P, (2001) Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 61: 3022-3026.
9. Wiewrodt R, Amin K, Kiefer M, Jovanovic VP, Kapoor V, et al. (2003) Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 10: 353-364.
10. Kagaya T, Nakamoto Y, Sakai Y, Tsuchiyama T, Yagita H, et al. (2006) Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ther 13: 357-366.
11. Ardiani A, Sanchez-Bonilla M, Black ME, (2010) Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo. Cancer Gene Ther 17: 86-96.
12. Ren W, Strube R, Zhang X, Chen SY, Huang XF, (2004) Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res 64: 6645-6651.
13. Yamazaki M, Straus FH, Messina M, Robinson BG, Takeda T, et al. (2004) Adenovirus-mediated tumor-specific combined gene therapy using Herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma. Cancer Gene Ther 11: 8-15.
14. Ihle JN, (1992) Interleukin-3 and hematopoiesis. Chem Immunol 51: 65-106.
15. Schrader JW, (1986) The panspecific hemopoietin of activated T lymphocytes (interleukin-3). Annu Rev Immunol 4: 205-230.
16. Frendl G, Beller DI, (1990) Regulation of macrophage activation by IL-3. I. IL-3 functions as a macrophage-activating factor with unique properties, inducing Ia and lymphocyte function-associated antigen-1 but not cytotoxicity. J Immunol 144: 3392-3399.
17. Pulaski BA, Yeh KY, Shastri N, Maltby KM, Penney DP, et al. (1996) Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc Natl Acad Sci U S A 93: 3669-3674.
18. McBride WH, Economou JS, Syljuasen RG, Parrish C, Hackman D, et al. (1996) The effects of cytokine gene transfer into tumors on host cell infiltration and regression. Anticancer Res 16: 1139-1143.
19. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, et al. (1993) Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res 53: 2112-2117.
20. Chiang CS, Syljuasen RG, Hong JH, Wallis A, Dougherty GJ, et al. (1997) Effects of IL-3 gene expression on tumor response to irradiation in vitro and in vivo. Cancer Res 57: 3899-3903.
21. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, et al. (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120: 694-705.
22. Tsai CH, Hong JH, Hsieh KF, Hsiao HW, Chuang WL, et al. (2006) Tetracycline-regulated intratumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer. Cancer Gene Ther 13: 1082-1092.
23. Stefani AL, Barzon L, Castagliuolo I, Guido M, Pacenti M, et al. (2005) Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. J Hepatol 42: 728-735.
24. Zhang JH, Wan MX, Yuan JY, Pan BR, (2004) Construction and identification of recombinant vectors carrying herpes simplex virus thymidine kinase and cytokine genes expressed in gastric carcinoma cell line SGC7901. World J Gastroenterol 10: 26-30.
25. Hanari N, Matsubara H, Hoshino I, Akutsu Y, Nishimori T, et al. (2007) Combinatory gene therapy with electrotransfer of midkine promoter-HSV-TK and interleukin-21. Anticancer Res 27: 2305-2310.
26. Frendl G, Fenton MJ, Beller DI, (1990) Regulation of macrophage activation by IL-3. II. IL-3 and lipopolysaccharide act synergistically in the regulation of IL-1 expression. J Immunol 144: 3400-3410.
27. Yeh KY, McAdam AJ, Pulaski BA, Shastri N, Frelinger JG, et al. (1998) IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes. J Immunol 160: 5773-5780.
28. Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG, (1998) IL-3-mediated enhancement of particulate antigen presentation by macrophages. J Immunother 21: 205-210.
29. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, et al. (1997) Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 71: 267-274.
30. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR, (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54: 6228-6234.
31. Ramesh R, Marrogi AJ, Munshi A, Freeman SM, (1998) Potentiation of the bystander effect by immunization combined with suicide gene therapy. Adv Exp Med Biol 451: 125-131.
32. Ramesh R, Munshi A, Abboud CN, Marrogi AJ, Freeman SM, (1996) Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 3: 373-384.
33. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G, (1994) Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci U S A 91: 9407-9411.
34. Nathan CF, Hibbs JB Jr, (1991) Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 3: 65-70.
35. Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR, et al. (1999) Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer 81: 889-896.